News

University of Toronto researchers have developed a new technology for creating more durable disease-fighting molecules which could lead to drugs with longer-lasting effects.

Injecting minute amounts of two immune-stimulating agents directly into solid tumors in mice can eliminate all traces of cancer in the animals, including distant, untreated metastases, according to a study by researchers at the Stanford University School of Medicine.

Neuroscientists ask, could klotho become a therapy for humans to improve brain health and protect against aging and disease?

Until now the use of adenoviruses in tumor therapy has been very limited. They lack the ability to infect cancer cells and therefore cannot inject the genetic blueprints for the therapeutic molecules to fight the disease. Researchers have now succeeded in rebuilding the viruses so that they effectively recognize and infect tumor cells.

James P. Allison was the first to demonstrate that immunotherapy can treat cancer effectively, initiating an approach that "has provided clinical benefit to many cancer patients" and "stimulated the development of a new class of drugs employing the immune system to fight cancer."

Osaka University researchers develop method to extract valuable information from gene expression level and DNA methylation modification data.

A team of scientists from the National University of Singapore (NUS) has developed a way to wirelessly deliver light into deep regions of the body to activate light-sensitive drugs for photodynamic therapy (PDT).

A test that measures the levels of two types of immune cell in the blood could identify which cancer patients are most likely to respond to immunotherapy.

New molecular research shows how chemically diverse drugs used to treat depression and anxiety disorders interact with the protein that transports serotonin in the brain. The discovery could open the way for the development of additional forms of antidepressants collectively known as selective serotonin reuptake inhibitors, or SSRIs.

Nicholas Cross appointed to guide development and growth of the Company,